Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Senior VP - CCO | January 25, 2019 | January 29, 2019 |
| BIORA THERAPEUTICS, INC.BIOR · Entity 85047 | Director | June 05, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2019-01-28 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2019-01-25 · Exercise / conversion · Acquired 6,000 · Balance 6,000 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Row 2 · 2019-01-25 · Sale · Disposed 6,000 · Balance 0 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.50 to $9.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Row 3 · 2019-01-28 · Exercise / conversion · Acquired 4,000 · Balance 4,000 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Row 4 · 2019-01-28 · Sale · Disposed 4,000 · Balance 0 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F3: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.85 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Row 5 · 2019-01-28 · Exercise / conversion · Acquired 2,000 · Balance 2,000 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Row 6 · 2019-01-28 · Sale · Disposed 2,000 · Balance 0 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F5: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.90 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23 | Direct | 85,427 |
Reported balance
After 2019-01-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-25 · Exercise / conversion · Disposed 6,000 · Balance 85,427 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23 | Direct | 81,427 |
Reported balance
After 2019-01-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-28 · Exercise / conversion · Disposed 4,000 · Balance 81,427 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23 | Direct | 79,427 |
Reported balance
After 2019-01-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-01-28 · Exercise / conversion · Disposed 2,000 · Balance 79,427 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.
F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.50 to $9.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.85 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018.
F5: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.90 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
BIORA THERAPEUTICS, INC.
Report date June 05, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,746 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 30,746 F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2034-06-05 | Direct | 12,500 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500 F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2018 Filed Nov 9, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 300 | $3.22 | $966.00 |
DisclosureSEC source: 0001127602-18-032640 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032413 · form4.xml · derivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,327 Underlying: Common Stock · 100 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 100 | $8.00 | $800.00 |
DisclosureSEC source: 0001127602-18-032413 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 100 | $3.22 | $322.00 |
DisclosureSEC source: 0001127602-18-032413 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032278 · form4.xml · derivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,427 Underlying: Common Stock · 1,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 1,000 | $8.00 | $8,000.00 |
DisclosureSEC source: 0001127602-18-032278 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 1,000 | $3.22 | $3,220.00 |
DisclosureSEC source: 0001127602-18-032278 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 18:17 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 1,544 | $7.51 | $11,595.44 |
DisclosureSEC source: 0001127602-18-032034 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $7.50 to $7.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 17:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 100 | $7.50 | $750.00 |
DisclosureSEC source: 0001127602-18-030769 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,149 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:15 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035403 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:49 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001127602-17-026944 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2025-01-26 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 20:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009161 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.